W
WAVEMAN · COMPANY
CALC · Calcimedica, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

CALC

CalciMedica, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001534133
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
$199.2K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
15
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$199.2K over 180 days
+$199.2K over 90 days · +$199.2K of it by a 10%+ holder
more than 79% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
15 funds added or opened last quarter
below 74% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
1.5% of shares outstanding short · 1.8 days to cover · settled 2026-07-31
below 68% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Alafi Capital Company LLC disclosed a 5%+ stake (17.1%) in the last six months.
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -30.0%
-30.0%12M
-84%-17%+50%+117%2025-092025-102025-122026-032026-052026-072026-09 2026-06-25 · Middleton Fred A bought $199.2K2025-09-12 · Roberts Eric W bought $15.6K2025-09-15 · Roberts Eric W bought $9.1K2025-09-18 · Roberts Eric W bought $7.7K2025-09-09 · Roberts Eric W bought $7.4K2026-07-10 · Alafi Capital Company LLC filed a 5%+ stake (17.1%)2026-07-10 · Christopher D. Alafi filed a 5%+ stake (17.1%)2026-07-02 · Bering Partners II GP, L.L.C. filed a 5%+ stake (6.9%)2026-07-02 · Bering Partners II, L.P. filed a 5%+ stake (6.9%)2026-07-02 · Evgeny Zaytsev filed a 5%+ stake (6.9%)2026-07-02 · Philip M Sawyer filed a 5%+ stake (6.9%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows a net $199.2K bought by insiders over 180 days, 15 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CalciMedica, Inc. insiders bought a net $199.2K of stock across 119 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Middleton Fred A
Director
BUY
2026-06-25
248,972.0
$199.2K
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-18
2,500.0
$7.7K
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-15
3,400.0
$9.1K
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-12
5,000.0
$15.6K
Roberts Eric W
CHIEF BUSINESS OFFICER
BUY
2025-09-09
2,343.0
$7.4K
119 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 114 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Woodline Partners LP
2,489,729.0 sh
$2.6M
Stonepine Capital Management, LLC
2,751,029.0 sh
$1.8M
HEIGHTS CAPITAL MANAGEMENT, INC
1,556,081.0 sh
$1.6M
Squadron Capital Management LLC
1,244,864.0 sh
$1.3M
STEMPOINT CAPITAL LP
1,244,864.0 sh
$1.2M
5%+ owners
13D = intent to influence · 13G = passive
Alafi Capital Company LLC
ACTIVIST 13D · 2026-07-10
17.1%
Christopher D. Alafi
ACTIVIST 13D · 2026-07-10
17.1%
Bering Partners II GP, L.L.C.
ACTIVIST 13D · 2026-07-02
6.9%
Bering Partners II, L.P.
ACTIVIST 13D · 2026-07-02
6.9%
Evgeny Zaytsev
ACTIVIST 13D · 2026-07-02
6.9%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
VANGUARD EXTENDED MARKET INDEX FUND
$48.0K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$24.1K POSITION · AS OF 2026-02-28
0.0%
Fidelity Nasdaq Composite Index Fund
$5.0K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$6.4K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$6.0K POSITION · AS OF 2026-02-28
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$43.3K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 5 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
5
Phase 2
0 ACTIVE
What changed recently
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
2026-09-01 · Active Not Recruiting → Terminated · The study was stopped due to imbalance in randomization stratification of severe patients.
Phase 2
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · A. Rachel Leheny
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$895.4K
$2.4M
$733.4K
+130%
—
2024
$1.7M
$1.5M
$1.3M
+24%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-23.1M$-24.2M$-38.1M$-14.2M
NET INCOME$-29.6M$-13.7M$-34.4M$-7.8M
EPS (DILUTED)-1.97-1.22-7.66-111.16
OPERATING CASH FLOW$-21.2M$-21.1M$-25.7M$-11.8M
CASH$11.5M$7.9M$5.5M$1.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →